Aranesp® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation,...
Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. LIMITATIONS OF USE • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
Aranesp™ is used to treat anemia (a lower than normal number of red blood cells) in patients with kidney disease who may or may not be on dialysis and to treat anemia in patients with cancer...
ARANESP (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. ARANESP is not intended for patients who require immediate correction of severe anemia or …
Aranesp is a prescription medicine used to treat anemia. People with anemia have a lower-than-normal number of RBCs. Aranesp works like the human protein called erythropoietin to help your body make more RBCs.
Before reading these instructions, read the Medication Guide that comes with Aranesp for the most important information you need to know. When you receive your Aranesp prefilled syringe make...
Aranesp® is a medicine that acts like a hormone in the body called erythropoietin. Aranesp® helps the body create more red blood cells. More red blood cells increase your hemoglobin (Hb) level, helping give your tissues and organs the oxygen they need to function properly.
ARANESP (darbepoetin alfa) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Anemia Due to Chronic Kidney Disease
Aranesp should be used with caution in patients with a history of seizures. Antibody-mediated Pure Red Cell Aplasia (PRCA) has been reported after months to years of treatment with erythropoiesis-stimulating agents (ESAs).